Topical dermatological formulations of non-steroidal anti-in‰ammatory drugs (NSAIDs) are reported to show their pharmacological eŠect partially through the systemic circulation, and to induce systemic side eŠects. However, pharmaceutical equivalence and pharmacokinetic bioequivalence between brand-name and generic products are not required. Therefore, we aimed to predict systemic drug exposure from brand-name and nine generic ketoprofen tapes. In vitro release proˆles were examined using the paddle-over-disk method, then analyzed by the W. I. Higuchi equation incorporating an initial burst eŠect. Pharmacokinetic parameters were estimated from observed release proˆles and the reported time-plasma concentration proˆle of the brand-name product. Plasma concentration proˆles of generic products were predicted from the observed release proˆles and the pharmacokinetic parameters of the brand-name product. In vitro release proˆles diŠered markedly, and estimated release rates for initial burst eŠect and at 24 hours ranged from 4.20 to 88.75％ and from 45.27 to 95.83％, respectively. The predicted plasma concentration proˆle of each product re‰ected its release proˆle, and estimated C max ranged from 61.70 to 290.30 ng/mL (0.46-to 2.15-fold vs. brand-name product). Generic products were classiˆed into three types, i.e., systemic exposure comparable with, higher than and lower than that of brand-name product. C max was predicted to increase with enhanced skin permeability for all products, but the increase rates diŠered among products. These results suggest that safety and e‹cacy diŠer between brand-name and generic ketoprofen tapes. Healthcare professionals should carefully monitor systemic side eŠects, especially when switching from brand-name to generic products for which higher systemic exposure is predicted. 
a: release rate for initial burst eŠect, b: release rate constant from tape compartment. a) Ratio of estimated Cmax of each product to that of product A (brand-name product). b) Ratio of estimated C max for normal ka to that in the case of increased skin permeability (10 times larger than ka). Type Medium_1: The extent of systemic exposure, a (release rate for initial burst eŠect) and b (release rate constant from tape) values are comparable with those of the brand-name ketoprofen tape. Type Medium_2: The extent of systemic exposure is comparable with that of the brand-name ketoprofen tape, and the a value is lower and the b value is higher than those of the brand-name ketoprofen tape. Type Low: The extent of systemic exposure is lower than that of the brand-name ketoprofen tape, and the a and b values are lower than those of the brand-name ketoprofen tape. Type High: The extent of systemic exposure is higher than that of the brand-name ketoprofen tape, and the a value is higher and the b value is lower than those of the brand-name ketoprofen tape. Since the a value is very large, the skin permeability (i.e., ka) alternation markedly aŠects the time-concentration proˆle. (B) Type medium (product A, C, F, H) and type low (product B): Since the a value is small and the b value is smaller than the ka value, the skin permeability (i.e., ka) alternation hardly aŠects the time-concentration proˆle. a: release rate for initial burst eŠect, b: release rate constant from tape, ka: permeation rate constant through skin, ke: elimination rate constant from blood compartment. 
